FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2790569086> ?p ?o ?g. }

• W2790569086 abstract "Background: The PAM (PI3K/Akt/mTOR) signaling pathway has been implicated in the oncogenesis of multiple solid malignancies, including breast cancer (BC). Tumor infiltrating lymphocytes (TILs) found within the tumor immune microenvironment (TME) are both prognostic of overall survival as well as predictive of response to neoadjuvant chemotherapy in BC. Our aim is to characterize the TME in a series of patients with operable stage I-III BC treated with MK-2206, an allosteric Akt inhibitor as part of a presurgical, window of opportunity, trial. In our presurgical trial (clinicaltrials.gov #: NCT01319539), patients received 2 doses of MK-2206 with first dose at day -9 and second at day -2 from surgery. Methods: Quantitative multiplex immunofluorescence (qmIF) was performed using immune biomarkers (DAPI, CD3, CD8, CD4, FOXP3, CD68, Pancytokeratin) on full section (4uM) tissue slides from core biopsy specimens and postsurgical specimens of 10 patients - 5 patient treated with MK-2206, and 5 prospectively collected untreated controls. Images were taken using Vectra, a novel pathology workstation and analyzed using inForm software to perform cell classification and phenotyping. Student T- test was used to compare biomarker changes before and after MK-2206. Results: Preliminary analysis demonstrates that patients treated with MK-2206 exhibited a significantly increased median cytotoxic T-cells (CD3CD8+) density, as compared to the matched control cohort (87% vs.0.2%, p Conclusions: In our study, we found that presurgical Akt inhibition lead to a significant increase in the cytotoxic T-cell population which was in similar proximity, if not closer, to tumor cells as compared to matched controls. Limitations of this exploratory study include a small patient cohort size and use of a single pathology evaluation technique. We are currently expanding our characterization of the TME with a more comprehensive myeloid panel as well as performing additional tissue analysis to validate our findings. At present, there are currently FDA approved therapies, as well as agents in clinical development that exert antineoplastic activity through the PAM pathway. Investigations that endeavor to understand the impact of these therapies on the TME may lead to both an increased understanding of the bioactivity of these agents and potentially identify aspects of the immune response which can be exploited by future immunotherapy therapeutics. Citation Format: Marks DK, Gartrell RD, Asmar ME, Hart TD, Lu Y, Esancy CL, Hibshoosh H, Connolly EP, Kalinsky KM, Saenger YM. Cytotoxic t-lymphocyte density increased within the tumor immune microenvironment of patients with breast cancer following treatment with Akt inhibitor MK-2206 [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P5-03-03." @default.
• W2790569086 created "2018-03-29" @default.
• W2790569086 creator A5002621737 @default.
• W2790569086 creator A5006770460 @default.
• W2790569086 creator A5024811283 @default.
• W2790569086 creator A5032257640 @default.
• W2790569086 creator A5035585352 @default.
• W2790569086 creator A5041290798 @default.
• W2790569086 creator A5059393674 @default.
• W2790569086 creator A5071599584 @default.
• W2790569086 creator A5084696219 @default.
• W2790569086 creator A5089042951 @default.
• W2790569086 date "2018-02-14" @default.
• W2790569086 modified "2023-10-14" @default.
• W2790569086 title "Abstract P5-03-03: Cytotoxic t-lymphocyte density increased within the tumor immune microenvironment of patients with breast cancer following treatment with Akt inhibitor MK-2206" @default.
• W2790569086 doi "https://doi.org/10.1158/1538-7445.sabcs17-p5-03-03" @default.
• W2790569086 hasPublicationYear "2018" @default.
• W2790569086 type Work @default.
• W2790569086 sameAs 2790569086 @default.
• W2790569086 citedByCount "0" @default.
• W2790569086 crossrefType "proceedings-article" @default.
• W2790569086 hasAuthorship W2790569086A5002621737 @default.
• W2790569086 hasAuthorship W2790569086A5006770460 @default.
• W2790569086 hasAuthorship W2790569086A5024811283 @default.
• W2790569086 hasAuthorship W2790569086A5032257640 @default.
• W2790569086 hasAuthorship W2790569086A5035585352 @default.
• W2790569086 hasAuthorship W2790569086A5041290798 @default.
• W2790569086 hasAuthorship W2790569086A5059393674 @default.
• W2790569086 hasAuthorship W2790569086A5071599584 @default.
• W2790569086 hasAuthorship W2790569086A5084696219 @default.
• W2790569086 hasAuthorship W2790569086A5089042951 @default.
• W2790569086 hasConcept C121608353 @default.
• W2790569086 hasConcept C126322002 @default.
• W2790569086 hasConcept C142724271 @default.
• W2790569086 hasConcept C143998085 @default.
• W2790569086 hasConcept C154317977 @default.
• W2790569086 hasConcept C167672396 @default.
• W2790569086 hasConcept C202751555 @default.
• W2790569086 hasConcept C203014093 @default.
• W2790569086 hasConcept C2776107976 @default.
• W2790569086 hasConcept C2778326572 @default.
• W2790569086 hasConcept C2779727006 @default.
• W2790569086 hasConcept C2908647359 @default.
• W2790569086 hasConcept C502942594 @default.
• W2790569086 hasConcept C530470458 @default.
• W2790569086 hasConcept C55493867 @default.
• W2790569086 hasConcept C62478195 @default.
• W2790569086 hasConcept C71924100 @default.
• W2790569086 hasConcept C75217442 @default.
• W2790569086 hasConcept C86554907 @default.
• W2790569086 hasConcept C86803240 @default.
• W2790569086 hasConcept C8891405 @default.
• W2790569086 hasConcept C99454951 @default.
• W2790569086 hasConceptScore W2790569086C121608353 @default.
• W2790569086 hasConceptScore W2790569086C126322002 @default.
• W2790569086 hasConceptScore W2790569086C142724271 @default.
• W2790569086 hasConceptScore W2790569086C143998085 @default.
• W2790569086 hasConceptScore W2790569086C154317977 @default.
• W2790569086 hasConceptScore W2790569086C167672396 @default.
• W2790569086 hasConceptScore W2790569086C202751555 @default.
• W2790569086 hasConceptScore W2790569086C203014093 @default.
• W2790569086 hasConceptScore W2790569086C2776107976 @default.
• W2790569086 hasConceptScore W2790569086C2778326572 @default.
• W2790569086 hasConceptScore W2790569086C2779727006 @default.
• W2790569086 hasConceptScore W2790569086C2908647359 @default.
• W2790569086 hasConceptScore W2790569086C502942594 @default.
• W2790569086 hasConceptScore W2790569086C530470458 @default.
• W2790569086 hasConceptScore W2790569086C55493867 @default.
• W2790569086 hasConceptScore W2790569086C62478195 @default.
• W2790569086 hasConceptScore W2790569086C71924100 @default.
• W2790569086 hasConceptScore W2790569086C75217442 @default.
• W2790569086 hasConceptScore W2790569086C86554907 @default.
• W2790569086 hasConceptScore W2790569086C86803240 @default.
• W2790569086 hasConceptScore W2790569086C8891405 @default.
• W2790569086 hasConceptScore W2790569086C99454951 @default.
• W2790569086 hasLocation W27905690861 @default.
• W2790569086 hasOpenAccess W2790569086 @default.
• W2790569086 hasPrimaryLocation W27905690861 @default.
• W2790569086 hasRelatedWork W11893065 @default.
• W2790569086 hasRelatedWork W12659739 @default.
• W2790569086 hasRelatedWork W13600379 @default.
• W2790569086 hasRelatedWork W14057612 @default.
• W2790569086 hasRelatedWork W14542699 @default.
• W2790569086 hasRelatedWork W164779 @default.
• W2790569086 hasRelatedWork W2482010 @default.
• W2790569086 hasRelatedWork W2744283 @default.
• W2790569086 hasRelatedWork W7207526 @default.
• W2790569086 hasRelatedWork W17139163 @default.
• W2790569086 isParatext "false" @default.
• W2790569086 isRetracted "false" @default.
• W2790569086 magId "2790569086" @default.
• W2790569086 workType "article" @default.